A few days ago, our team, comprising Melissa Van Pel, David W., Yasmin Habani, Conor Vogelzang, and Tristan Pritchard-Meaker, visited bioMérieux in Lyon to strengthen our partnership further and explore the forefront of Cell and Gene Therapy (CGT). We explored current trends and developments within the CGT field during our visit. Additionally, we were given a tour of bioMérieux’s state-of-the-art specialist manufacturing facilities, where we observed their advanced processes firsthand! Our collaborative session on Quality Control (QC) applications in CGT was a significant highlight. We shared our feedback and user experiences, identified unmet needs in our field, and discussed the potential to further support and enhance QC processes. This exchange of ideas is crucial for pushing the boundaries of what’s possible in CGT. Melissa gave an insightful presentation on CGT/NecstGen projects, showcasing our ongoing initiatives and future goals. Her presentation underscored our commitment to innovation and excellence in the field. We look forward to our continued collaboration! #cellandgenetherapy #qualitycontrol #innovation #partnership #bioMérieux
NecstGen’s Post
More Relevant Posts
-
As announced last week, we are today launching our portrait series dedicated to the eminent members of CELLforCURE by Seqens scientific Advisory Board. The aim of this initiative is to highlight the exceptional personalities who contribute to our mission of developing and manufacturing the Cell and Gene therapies of today and tomorrow. To launch this series, we are honored to present the portrait of Pascale Bouillé, who has agreed to join our Scientific Advisory Board. Pascale Bouillé is a recognized expert in the field of biotechnology, and brings invaluable experience in the development of innovative therapies. Stay tuned for future profiles in our series, and learn more about the members of CELLforCURE by Seqens Scientific Advisory Board. Our Science for your future #CELLforCURE #ScientificBoard #GeneCellTherapies #Innovation #RegenerativeMedicine #Partnerships #Ourscienceforyourfuture
-
Engaging discussion on the challenges, emerging trends, and key value drivers shaping the Cell & Gene Therapy (C>) space, as well as the potential growth opportunities in Europe at Advanced Therapies Europe 2024. At Invivo Partners, we’re confident that the C> field will continue to advance, with promising expansions into new indications, the exploration of novel cell types, and the development of cutting-edge technologies to tackle the challenges ahead. #ATE24
-
-
To navigate the intricate challenges that define #CGT distribution, a forward-thinking approach is foundational to achieving commercial success. In an interview with Pharm Exec, Cencora’s Melissa Lattanzi, Vice President, Emerging Therapies, delves into crucial considerations that cell and gene therapy (CGT) developers must address to shape an effective distribution strategy ⬇️ https://ow.ly/GuyI50SEvb1
-
-
Strategic Leadership | Healthcare Executive | Business Development | Cross-functional Collaboration | Operations Management
A coordinated orchestration with tailored services, distribution and advanced analytics is critical to unlocking value for our CGT partners.
To navigate the intricate challenges that define #CGT distribution, a forward-thinking approach is foundational to achieving commercial success. In an interview with Pharm Exec, Cencora’s Melissa Lattanzi, Vice President, Emerging Therapies, delves into crucial considerations that cell and gene therapy (CGT) developers must address to shape an effective distribution strategy ⬇️ https://ow.ly/GuyI50SEvb1
-
-
📣 We are kicking off the fall conference season with BPI Boston! Looking to drive up batch productivity and drive down manufacturing COGS? Here are two ways our Viral Sensitizers (VSEᵀᴹ) cell enhancers can tackle the challenge of innate cellular defenses during cell and gene therapy (CGT) production: ✔ A tailored formulation of VSEs optimized for your platform, cell substrate and viral product. ✔ Achieve higher yields and improved quality - validated in 50+ applications across cell lines and viral products. 💡 Unlock the potential of your production platform with our VSEs and Design of Experiments (DoE) expertise to optimize viral vector production and boost viral yields rapidly. 🤝 If you are attending, swing by booth #1811! We'd love to chat! Check out our technology: https://lnkd.in/gu2m3RcX #biomanufacturing #BPIBoston #innovation #biotechnology
-
-
Do you want to learn about the latest advancements in secure and reliable shipping for high-value gene therapies? Join Cryoport & CRYOPDP at the Cell & Gene by Oxford Global conference! Catch us at booth 11! Don't miss out - See you there! #genetherapy #logistics #transport #supplychain
🗓️ Meet us at the London Gene Therapy Development 2024 in Booth #11 event. Join us from June 13th to 14th at the Gene Therapy Development 2024—Booth #11 event in London alongside Cryoport. Explore cold chain logistics solutions and meet Filipa Gonçalves and Jane Wells, our temperature-controlled experts. See you there! Let's create extraordinary opportunities! Click here to learn more about our events, and contact us: https://lnkd.in/d6gaDuQg. #genetherapy #biotechnology #logistics #transport
-
-
Vice President of Business Development @ Matica Biotechnology | CGT Commercial Development & Sales
Reach out to learn more about how our dedicated team here at Matica Biotechnology, Inc. can help meet your virally modified cell therapy or gene therapy preclinical production and cGMP clinical manufacturing needs! We have put together very creative options around financing strategies to support the unique needs of early stage developers (pre-clinical and early stage clinical) through these currently difficult times in the market. Just ping me to learn more! #viralvector #genetherapy #celltherapy #cGMP #ProcessDevelopment
[Elevate Your Viral Vector Production with Matica Bio] At Matica Bio, we specialize in streamlining process development for viral vectors, ensuring you achieve optimal scalability and efficiency. Our cutting-edge solutions, powered by high-performing MatiMax cell line, are designed to drive down manufacturing costs without compromising quality. Our team of seasoned scientists, experts in cell and gene therapy, are committed to delivering precision and excellence at every stage of development. Let’s partner to take your program to next stage. Contact us today to learn more about how we can propel your advancements together. www.maticabio.com #genetherapy #celltherapy #processdevelopment #innovations
-
-
Get exclusive insights from Jennifer Fenwick, Senior Manager Personalized Supply Chain at World Courier, and Dr. Matthew Lakelin, VP Scientific Affairs and TrakCel Co-Founder in this informative Q&A. They unravel the complexities of cell and gene therapy (CGT) supply chains, how they revolutionize conventional healthcare sectors and the unique challenges this emerging field faces. Explore how digitalization and integration can enhance efficiency, reduce errors and ensure timely delivery of life-saving therapies to patients: https://lnkd.in/edqjc7E2
-
-
How is investment within the cell and gene therapy sector trending in 2024? Our Q1 2024 Data shows it was a strong quarter. 📊 There was $7.1 billion in total investments in Q1 2024, over 50% of total investments for all of 2023. Of that, $6 billion came from the North American region. What does the full picture look like? Dive into our Q1 2024 Sector Data to learn more. ➡ https://lnkd.in/ebJw3Kxi #cellandgenetherapy
-
-
The development of transformative cell and gene therapies (CGTs) requires bounds of time, expertise, and financial resources — ensuring that patients can truly reap the benefits of your innovation is essential. Unlock the full potential of your product and make the most of your investments by following this step-by-step guide to CGT commercialization. Download now https://lnkd.in/ecn9SSNq
-
